<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202601</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI310Y101</org_study_id>
    <nct_id>NCT04202601</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer</brief_title>
  <official_title>Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of sintilimab+ IBI310 for&#xD;
      EBV-Positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 13, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arms 1: Neoadjuvant therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Pathological complete regression (pCR):&#xD;
Pathological complete regression (pCR) is defined as the proportion of patients with pathological complete regression (TRG1a) over the total number of patients evaluated centrally by the study pathologist</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arms 2: first-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Objective response rate(ORR):&#xD;
Objective response rate(ORR) of Sintilimab in combination with IBI310 in all participants in this group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arms 3:≥second-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Objective response rate(ORR):&#xD;
Objective response rate(ORR) of Sintilimab in combination with IBI310 in all participants in this group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arms 1: Neoadjuvant therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>R0 resection rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1: Neoadjuvant therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Event free survival(EFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1: Neoadjuvant therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Objective response rate(ORR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1: Neoadjuvant therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Disease control rate(DCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1: Neoadjuvant therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Overall survival(OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 1: Neoadjuvant therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Number of participants experiencing clinical and laboratory adverse events (AEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 2: first-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Progression-free survival (PFS）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 2: first-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Disease control rate (DCR）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 2: first-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Overall survival (OS）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 2: first-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>( Number of participants experiencing clinical and laboratory adverse events (AEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 3:≥second-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Progression-free survival (PFS）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 3:≥second-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Disease control rate (DCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 3:≥second-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Overall survival (OS）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms 3:≥second-line therapy group</measure>
    <time_frame>Approximately 40 months after the first participant is randomized</time_frame>
    <description>Number of participants experiencing clinical and laboratory adverse events (AEs)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>first-line therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>≥second-line therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Arms 1: Neoadjuvant therapy group 20 patients Drug: Sintilimab Weight&lt;60Kg: 3mg/kg Q3W Weight&gt;=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Perioperative Sintilimab+IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .&#xD;
Arms 2: first-line therapy group, 30 patients Drug: Sintilimab Weight&lt;60Kg: 3mg/kg Q3W Weight&gt;=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.&#xD;
Arms 3: ≥second-line therapy group, 30 patients Drug: Sintilimab Weight&lt;60Kg: 3mg/kg Q3W Weight&gt;=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.</description>
    <arm_group_label>Neoadjuvant therapy group</arm_group_label>
    <arm_group_label>first-line therapy group</arm_group_label>
    <arm_group_label>≥second-line therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI310</intervention_name>
    <description>Arms 1: Neoadjuvant therapy group, 20 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Perioperative Sintilimab+ IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .&#xD;
Arms 2: first-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.&#xD;
Arms 3: ≥second-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.</description>
    <arm_group_label>Neoadjuvant therapy group</arm_group_label>
    <arm_group_label>first-line therapy group</arm_group_label>
    <arm_group_label>≥second-line therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has histologically confirmed diagnosis of unresectable locally advanced,recurrent or&#xD;
             metastatic gastric or GEJ malignant tumor (including squamous carcinoma,&#xD;
             adenocarcinoma, Signet-ring cell carcinoma).&#xD;
&#xD;
          -  Confirmed EBV positive determined by in situ hybridization (ISH), analyzed with tumor&#xD;
             tissue sample, either from a previous surgery or biopsy , within last 6 months&#xD;
&#xD;
          -  Male or Female at least 18 years of age&#xD;
&#xD;
          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Has adequate organ function.&#xD;
&#xD;
          -  Expected survival&gt;=12 weeks&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy&#xD;
             test at the timing of enrollment.&#xD;
&#xD;
          -  Participants of childbearing potential must be willing to use an adequate method of&#xD;
             contraception for the course of the study through 6 months after the last dose of&#xD;
             study medication.&#xD;
&#xD;
        Applied to Arms 1: Has histologically confirmed gastric/GEJ malignant tumor, and were&#xD;
        regarded as having clinical stage T3-T4aN0M0 or T2～4aN+M0&#xD;
&#xD;
        Applied to Arms 2: Had no prior systemic treatment for metastatic disease.&#xD;
&#xD;
        Applied to Arms 3: Received ≥1 prior systemic treatment for metastatic disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has received prior therapy with an anti-programmed death (PD)-1, antiPD-L1, anti-PD&#xD;
             L2, anti-CTLA-4 agent or with an agent directed to another stimulatory or&#xD;
             co-inhibitory T-cell receptor&#xD;
&#xD;
          -  Is currently participating in and receiving study therapy ,except those in the&#xD;
             survival follow up period of an investigational agent study or non-interventional&#xD;
             study .&#xD;
&#xD;
          -  Received systemic treatment with corticosteroids (&gt; 10 mg daily prednisone equivalent)&#xD;
             or other immunosuppressive medications within 4 weeks of first dose. Inhaled or&#xD;
             topical steroids ,adrenal replacement steroid doses and steroid of prevention allergic&#xD;
             reaction of i.v. contrast agent are permitted in the absence of active autoimmune&#xD;
             disease.&#xD;
&#xD;
          -  Received a live vaccine within 4 weeks of the first dose of study medication or plan&#xD;
             to receive live vaccine during study period.&#xD;
&#xD;
          -  Has had major surgery (craniotomy, thoracotomy or laparotomy) within 4 weeks prior to&#xD;
             first dose of study medication, or anticipation of the need for major surgery during&#xD;
             the course of study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lin Shen, professor</last_name>
    <phone>86-10-88196561</phone>
    <email>linshenpku@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhi Peng, Associate Professor</last_name>
    <phone>86-10-88196561</phone>
    <email>zhipeng3@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shen Lin, Professor</last_name>
      <phone>010-88196561</phone>
      <email>Linshenpku@163.com</email>
    </contact>
    <investigator>
      <last_name>Shen Lin, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>MD,Professor,Chief of Department of GI Oncology,Peking University Cancer Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

